Specialty Urology
-
Featured
New Research Supports Trimodality Therapy for Bladder Cancer
A new Massachusetts General Hospital study compares bladder cancer treatment options and strongly supports bladder preservation with trimodality therapy.
-
Featured
Study Explores Value of Prostate Cancer Screening With MRI
The Prostate Cancer Genetics Program at Massachusetts General Hospital explores whether MRI prostate cancer screening detects disease earlier than standard tests in men with genetic mutations linked to prostate cancer.
-
MRI Enhances Early Detection of Prostate Cancer in Men at High Genetic Risk
Andrew Amini, MD, Keyan Salari, MD, PhD, and team report prostate MRI is a highly sensitive modality for early detection of prostate cancer, particularly clinically significant disease. MRI-based screening resulted in greater net clinical benefit than the traditional strategy of measuring prostate-specific antigen.
-
Multiparametric MRI Is Often False-Negative for Clinically Significant Prostate Cancer
Chin-Lee Wu, MD, PhD, Douglas M. Dahl, MD, and colleagues found that 15% of patients who had negative prostate multiparametric MRI (mpMRI) were diagnosed by 20-core standard template biopsy as having clinically significant prostate cancer. They recommend considering standard biopsy regardless of negative mpMRI.
-
Potential Strategy Identified for Treating Bone-Metastatic Clear Cell RCC
Shenglin Mei, PhD, and colleagues used single-cell RNA sequencing to construct a transcriptomic atlas of cells in the microenvironment of human bone-metastatic clear cell renal cell carcinoma and identified a subpopulation of mesenchymal stromal cells as a potential therapeutic target.
-
Less Aggressive Protocol Suitable for Muscle-invasive Bladder Cancer in Noncystectomy Candidates
Douglas M. Dahl, MD, Jason A. Efstathiou, MD, DPhil, and colleagues determined that in patients with muscle-invasive bladder cancer who were not candidates for cystectomy or cisplatin, maximum tumor resection and chemoradiation were associated with high response rates and five-year overall survival rates of 25% to 38%.
Urology Contributors
-
Adam S. Feldman, MD, MPH
Director, Combined Harvard Urologic Oncology Fellowship, Associate Chair for Research, Urologic Oncologist, Department of Urology, Massachusetts General Hospital, Associate Professor of Surgery, Harvard Medical School
Recent Article
Urine Test Validated for Diagnosis, Surveillance and Risk Prediction in Urothelial Carcinoma
-
Ajay Nehra, MBBS
Director of Men's Health and Male Reconstructive Surgery, Senior Urologic Surgeon
Recent Article
Establishing Guidelines for Peyronie's Disease
-
Brian H. Eisner, MD
Co-Director, Kidney Stone Program, Massachusetts General Hospital, Associate Professor of Surgery, Harvard Medical School
Recent Article
Pharmacologic Management of Ureteral Stent–related Symptoms Should Be Personalized
-
Dianne E. Sacco, MD
Co-Director, Kidney Stone Program, Assistant Professor of Surgery, Harvard Medical School
-
Douglas M. Dahl, MD
Chief, Division of Urologic Oncology, Vice-Chair, Department of Urology, Massachusetts General Hospital, Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers, Mass General Cancer Center, Associate Professor of Surgery (Urology), Harvard Medical School
Recent Article
Multiparametric MRI Is Often False-Negative for Clinically Significant Prostate Cancer
-
-
Keyan Salari, MD, PhD
Director of Translational Research, Urologic Surgeon, Department of Urology, Massachusetts General Hospital, Director, Prostate Cancer Genetics Program, Mass General Cancer Center, Assistant Professor of Surgery, Harvard Medical School
Recent Article
MRI Enhances Early Detection of Prostate Cancer in Men at High Genetic Risk
-
Matthew F. Wszolek, MD
Chair of Quality and Safety, Department of Urology, Massachusetts General Hospital, Urological Oncologist, Mass General Cancer Center, Instructor in Surgery, Harvard Medical School
Recent Article
Mortality Related to Surgical Staplers and Clip Appliers Is Increasing
Urology Care at Mass General
The Department of Urology at Massachusetts General Hospital offers sophisticated, compassionate care and the most innovative treatments for patients with any type of urological condition.